Bioprinting is a promising technology that offers hope to patients on the notoriously lengthy waiting lists for organ donation. Not unlike additive manufacturing, bioprinting involves 3D printing technology but instead uses organic material. The aim is to imitate natural tissue for a range of applications, including drug discovery, tissue engineering, and regenerative medicine.

Flow cytometry is a popular analytical technique used in research and clinical laboratories. The process uses a laser to quickly analyze a population of cells submersed in fluid. Flow cytometry serves a variety of uses, from cell counting and biomarker detection to protein engineering. This laser-based technique has helped scientists diagnose immunodeficiencies over the past decade, though its applications range from marine biology to pathology.

Covid-19 created shockwaves across every area of society, and the kidney disease industry is no exception. Doctors soon discovered a common consequence of Covid-19 was acute kidney disease (AKI), and with it came a troubling high mortality rate. 

Microchips. We’re all familiar with them. They’re used in our phones, our computers, and are often embedded into our pets. But the idea of fusing technology with human biology is an idea many people are, quite understandably, far less comfortable with.

The cell is one of the most basic units of life. While some cells are organisms in their entirety, like the microscopic amoeba, others only function as part of larger organisms – like the cells that make up our hair, brain, and skin. Cells are the building blocks of life, the very fiber of our existence, and can tell us a huge amount about human physiology. Because of their high physiological relevance, primary cells represent a promising sector of the market. Primary cells paint an accurate picture of how a human might respond to a certain drug or process. They are isolated directly from living human tissue, as opposed to manufactured cell lines, which are drawn from the already isolated primary cell culture.

Biotechnology is fundamental to the continued growth and advancement of modern life. With cancer cases rising, the number of genetically occurring diseases increasing, and food production chains threatened by pests and disease, creating biologically engineered solutions to these issues is more crucial than ever.

Whether you refer to it as The Big C, a malignant neoplasm, or its simpler name; cancer, we all know what it is and have all heard and seen the detrimental effect it has on those fighting and living with it every day. With a devastating mortality rate and a plethora of heart-breaking films, podcasts, and charities to remind us why research is so fundamental, cancer is one disease we can’t seem to sweep under the rug. According to Stand Up to Cancer (SU2C) UK, one in two of us will get cancer in our lifetime which, as a harrowing statistic in itself, means that funding cancer research and the development of potential cures is vital.

The genome-editing market offers a wealth of opportunity for the life science and healthcare industries. With the incidence of genetic disorders on the up, and growing applications in drug discovery and development, the market is being pushed into rapid growth. BCC Research’s latest report predicts the market will grow at a Compound Annual Growth Rate (CAGR) of 24.7% from 2022-2027. Given this hefty increase, we can expect to see significant advancements in disease treatments, helping drive the market further.

With the rising prevalence of life-threatening diseases and genetic disorders, the protein sequencing global market is set to increase in value for better diagnostic tools and biomarkers.

Synthetic biology has established itself as a vital component of the life science industry in recent years. Combining principles of engineering with molecular biology, synthetic biology has achieved immense worldwide success. So much so, that by 2026, the market is expected to achieve a compound annual growth rate of more than 28% by 2026.